Tripep Ab

Chrontech Pharma Ab

Anders Vahlne

Matti Sällberg

Maria Perdomo

Laura Goobar-Larsson

Sarah Sandin-Reneby

Jin Su

Stefan H&ouml;glund

&Aacute;kos V&eacute;gv&aacute;ri

Csaba Het&eacute;nyi

David Van Der Spoel

Peter Wagner

Robert Kamen

Gregor Schürmann

Albert Collinson

Disclosed are methods for identifying high affinity adaptor molecules that bind to both a circulating antibody and a target molecule and redirect the specificity of the circulating antibody to the target molecule. Exemplary high affinity adaptor molecules are also provided.

High affinity adaptor molecules for redirecting antibody specifity

The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.

Glycosylated specificity exchangers

Embodiments relate to the discovery that certain tripeptide amides and glycine amide can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising said tripeptide amides and/or glycine amide and methods of using said compounds for the prevention and treatment of viral infection, such as HIV infection, are provided.

Antiviral composition comprising glycine amide

Embodiments relate to the discovery that tripeptide amides, which correspond to viral capsid sequences, can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising tripeptide amides and methods of using said compounds for the prevention and treatment of viral infection, such as HIV infection, are provided.

Tripeptide amides that block viral infectivity and methods of use thereof

The present invention relates to the discovery that a specific pentamer peptide amide, which corresponds to a viral capsid sequence, can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising said pentamer peptide amide and methods of using said compounds for the prevention and treatment of viral infection, such as HIV infection, are provided.

Pentamer peptide amide, ALGPGNH2, which inhibits viral infectivity and methods of use thereof

The present invention relates to the discovery that a specific pentamer peptide amide, ALGPG-NH , which corresponds to a viral capsid sequence, can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising said pentamer peptide amide and methods of using said compounds for the prevention and treatment of viral infection, such as HIV infection, are provided.

Pentamer peptide amide, ALGPG-NH2, that inhibits viral infectivity and methods of use thereof

The discovery of peptides in amide form that inhibit viral infection, including human immunodeficiency virus (HIV) infection is disclosed. Methods of use of peptides are also disclosed including use in medicaments for the treatment and prevention of viral infection, such as HIV infection.

Growing community of inventors

Stockholm, Sweden

Anders Vahlne